Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Sanofi ADR(SNY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SNY
09/28/2026: SNY (1-star) is currently NOT-A-BUY. Pass it for now.
Sanofi is a prominent global pharmaceutical company with a leading position in immunology and vaccines. Its investment story is centered on the success of its flagship biologic, Dupixent, and a strategic pivot toward high-margin specialty care through the divestiture of its consumer healthcare business. While the firm benefits from strong research capabilities and stable revenue streams from its vaccine division, it faces execution risks regarding its pipeline and intense competition in inflammatory drug markets. The stock typically suits value-oriented and income-focused investors looking for stability in the healthcare sector. Key developments to monitor include Dupixent's continued label expansion and the long-term impact of its focused business strategy.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Growth is steady but tethered to specific product life cycles rather than explosive market expansion. |
| Momentum investor | Weak fit | The stock typically exhibits slow, stable price action rather than high-velocity momentum. |
| Value investor | Strong fit | Sanofi often trades at reasonable valuation multiples relative to its earnings and R&D portfolio. |
| Dividend investor | Strong fit | The company offers a reliable dividend yield that appeals to long-term income-oriented investors. |
| Low-risk investor | Strong fit | Its large-cap, essential-product business model provides relative stability during market downturns. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Low | Pharmaceutical sector stability tends to mitigate extreme price swings. |
| Valuation risk | Low | The stock generally trades in line with sector averages, limiting extreme overvaluation. |
| Competition risk (Biologics) | Medium / high | Intense competition in the immunology space from rivals like LLY and ABBV puts pressure on pricing. |
| Business quality | Strong | Sanofi possesses a high-quality portfolio of essential specialty drugs and vaccines. |
| Dividend income | Medium | Dividends are reliable, though they may not be as high-yielding as some pure-play income stocks. |
| Execution risk | Medium | The success of the R&D pipeline is critical for long-term growth and margin maintenance. |
Price Behavior
Flat / Range-Bound
The stock price has been trading within a narrow range with minimal directional movement.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit -21.57% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 98.51B USD | Price to earnings Ratio 22.34 | 1Y Target Price 53.72 |
Price to earnings Ratio 22.34 | 1Y Target Price 53.72 | ||
Volume (30-day avg) 2.3M shares | Beta 0.28 | 52 Weeks Range 40.66 - 49.91 | Updated Date 09/27/2026 |
52 Weeks Range 40.66 - 49.91 | Updated Date 09/27/2026 | ||
Dividends yield (FY) 10.06% | Basic EPS (TTM) 1.84 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Specialty Care | Immunology, rare diseases, and oncology drugs (e.g., Dupixent). | This is the primary engine for future growth and profitability. |
| Vaccines | Influenza, polio, and travel vaccines. | Provides stable, recurring, and high-margin revenue streams. |
| General Medicines | Established cardiovascular and diabetes treatments. | Provides steady cash flow to fund new R&D projects. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 22.34 | Forward PE 8.59 | Enterprise Value 121.92B | Price to Sales(TTM) 2.01 |
Enterprise Value 121.92B | Price to Sales(TTM) 2.01 | ||
Enterprise Value to Revenue 2.17 | Enterprise Value to EBITDA 12.89 | Shares Outstanding 2.40B | Shares Floating 2.16B |
Shares Outstanding 2.40B | Shares Floating 2.16B | ||
Percent Insiders - | Percent Institutions 8.02 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Sanofi ADR
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2002-07-01 | CEO & Director Ms. Belen Garijo Lopez M.D. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 74846 | Website https://www.sanofi.com |
Full time employees 74846 | Website https://www.sanofi.com | ||
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.